Data Collection Improves Patient Outcomes in Hospice, Palliative Care
the Cancer Therapy Advisor take:
Routine data collection and feedback at point-of-care improves most patient outcomes in hospice and palliative care, according to a recent study published in Supportive Care in Cancer.
David Currow, MD, and fellow researchers at Flinders University in Adelaide, Australia, examined data from 19,747 patients taken from the Australian Palliative Care Outcomes Collaboration in order to measure outcomes in the last three years. Point-of-care data points were set from July to December of 2008, subsequently compared to baseline data in six different six-month cycles for all submitted data.
The researchers found significant improvements across all domains of symptom control, family care, as well as psychological and spiritual care. However, they found no improvement in pain.
Additionally, they noted that interquartile ranges had decreased, which was indicative of better and more consistent patient outcomes that were being achieved with more data collection.
“These are the first national hospice/palliative care symptom control performance data to demonstrate improvements in clinical outcomes at a service level as a result of routine data collection and systematic feedback,” the authors concluded.
Routine data collection and feedback at point-of-care improves most patient outcomes in hospice and palliative care.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer